| [1] |
Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2009,27(11):1836-1843. DOI: 10.1200/JCO.2008.17.5844.
doi: 10.1200/JCO.2008.17.5844
pmid: 19273711
|
| [2] |
Cazzaniga ME, Camerini A, Addeo R, et al. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development[J]. Future Oncol, 2016,12(3):373-387. DOI: 10.2217/fon.15.306.
doi: 10.2217/fon.15.306
pmid: 26584409
|
| [3] |
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004,22(9):1589-1597. DOI: 10.1200/JCO.2004.08.163.
doi: 10.1200/JCO.2004.08.163
pmid: 15117980
|
| [4] |
Qi WX, Tang LN, He AN, et al. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 2012,138(5):745-751. DOI: 10.1007/s00432-012-1155-9.
pmid: 22258853
|
| [5] |
Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice[J]. J Clin Invest, 2000,105(8):1045-1047. DOI: 10.1172/JCI9872.
doi: 10.1172/JCI9872
pmid: 10772648
|
| [6] |
Kontopodis E, Hatzidaki D, Varthalitis I, et al. A phase Ⅱ study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase Ⅱ study of the Hellenic Oncology Research Group[J]. J Chemother, 2013,25(1):49-55. DOI: 10.1179/1973947812Y.0000000050.
pmid: 23433445
|
